Literature DB >> 9116314

Seasonal variation in the secretion of mammotrophic hormones in normal women and women with previous breast cancer.

I M Holdaway1, B H Mason, E E Gibbs, C Rajasoorya, A Lethaby, K D Hopkins, M C Evans, T Lim, B Schooler.   

Abstract

Hormones such as melatonin whose serum concentrations vary seasonally have been previously implicated in the growth of breast cancer. The present study was undertaken to identify possible seasonal variation in a range of mammotrophic hormones which could exert a chronobiologic influence in women with breast tumours. Fifteen premenopausal women with a history of previous breast cancer (BC subjects) and 10 control women underwent 2-hourly serum sampling for 24 h at both summer and winter solstice for measurement of melatonin, growth hormone (GH), insulin-like growth factor-I (IGF-I), cortisol, prolactin and thyrotrophin (TSH). Hormone secretion at the different seasons was compared by measuring the area under the 24 h serum hormone concentration x time curves and by time series analysis of summer-to-winter differences in hormone concentration. Control women had significantly higher GH and IGF-I levels in summer compared to winter and significantly higher cortisol secretion in winter than summer. In contrast, BC women had no significant seasonal difference in IGF-I concentrations and had a reversal of the normal seasonal pattern of melatonin secretion, although seasonal changes in GH production were similar to controls. Prolactin and TSH showed no significant summer/winter variation in either group. Thus, seasonal variations in hormone secretion seen in normal women were, with exception of GH, absent or reversed in women with a previous history of breast cancer. As a result these individuals may be exposed to an asynchronous hormonal stimulus which could influence tumour growth. These changes could reflect a constitutional abnormality in BC women or may have been induced by the previous breast tumour.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9116314     DOI: 10.1023/a:1005743626105

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  2 in total

1.  A randomized controlled trial of oral melatonin supplementation and breast cancer biomarkers.

Authors:  E S Schernhammer; A Giobbie-Hurder; K Gantman; J Savoie; R Scheib; L M Parker; W Y Chen
Journal:  Cancer Causes Control       Date:  2012-02-28       Impact factor: 2.506

2.  Overexpression of c-erbB2 is an independent marker of resistance to endocrine therapy in advanced breast cancer.

Authors:  S J Houston; T A Plunkett; D M Barnes; P Smith; R D Rubens; D W Miles
Journal:  Br J Cancer       Date:  1999-03       Impact factor: 7.640

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.